Skip to main content
. 2022 Aug 18;27(12):1041–1047. doi: 10.1093/oncolo/oyac158

Figure 1.

Figure 1.

Progression-free survival in 52 advanced MiT family translocation RCCs treated with cabozantinib at any line.